Last reviewed · How we verify
R2: Lenalidomide + ixazomib maintenance
Lenalidomide and ixazomib work together as immunomodulatory and proteasome inhibitor agents to enhance anti-myeloma immune responses and suppress tumor cell proliferation in multiple myeloma maintenance therapy.
Lenalidomide and ixazomib work together as immunomodulatory and proteasome inhibitor agents to enhance anti-myeloma immune responses and suppress tumor cell proliferation in multiple myeloma maintenance therapy. Used for Multiple myeloma maintenance therapy (post-induction treatment).
At a glance
| Generic name | R2: Lenalidomide + ixazomib maintenance |
|---|---|
| Also known as | Revlimid, Ninlaro |
| Sponsor | University of Leeds |
| Drug class | Immunomodulatory agent + proteasome inhibitor combination |
| Target | Cereblon (lenalidomide); 20S proteasome (ixazomib) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Lenalidomide is an immunomodulatory drug (IMiD) that enhances T-cell proliferation, NK cell activation, and TNF-α production while inhibiting angiogenesis. Ixazomib is a proteasome inhibitor that blocks NF-κB signaling and induces apoptosis in myeloma cells. Together in maintenance therapy, they provide dual mechanisms to prevent relapse and prolong progression-free survival in multiple myeloma patients.
Approved indications
- Multiple myeloma maintenance therapy (post-induction treatment)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Peripheral neuropathy
- Diarrhea
- Fatigue
- Infection
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- R2: Lenalidomide + ixazomib maintenance CI brief — competitive landscape report
- R2: Lenalidomide + ixazomib maintenance updates RSS · CI watch RSS
- University of Leeds portfolio CI